Please see current list of sites on ClinicalTrials.gov

• Southampton General Hospital (email HepatologyResearch@uhs.nhs.uk)
• Royal Victoria Hospital, Belfast (email allison.lloyd@belfasttrust.hscni.net)
• John Radcliffe, Oxford (email Victoria.Skinner@ouh.nhs.uk)
• King's College Hospital, London (email KCH-tr.AILD@nhs.net)
• Queen Elizabeth Hospital, Birmingham (email palak.trivedi@uhb.nhs.uk)
• St James's University Hospital, Leeds (ON HOLD -email leedsth-tr.leedsliverresearch@nhs.net)
• Royal Free Hospital, London (email mia.demesa@nhs.net)
• Addenbrooke's Hospital, Cambridge (abigail.ford4@nhs.net)
• Royal Infirmary, Edinburgh (email michael.williams@nhslothian.scot.nhs.uk)

More sites coming soon.

If you contact the centres above, please provide details of your
- current hospital and consultant
- current medications

***THIS STUDY IS NOT FOR PEOPLE WHO HAVE HAD TRANSPLANTS***

If you think you are eligible (suitable) and you want to take part but your hospital is not running the trial, it is still possible to take part.

Talk to your PSC doctor or contact the nearest study site to you. Some people switch hospitals temporarily for the duration of the clinical trial so that their PSC care and clinical trial study visits are at the same hospital; or they have a 'shared care' agreement whereby they still see their regular hospital doctor but also the PSC specialist who is running the clinical trial. Most PSC doctors will be supportive and coordinate this for you.

Please get in touch with us at hello@pscsupport.org.uk if you need help joining a clinical trial at a different hospital.

The VISTAS study is investigating the effect of a drug called volixibat on itch experienced by people with PSC.

Volixibat is an investigational medicinal product that is designed to block the main transporter protein (ileal bile acid transporter [IBAT]) that is normally responsible for bringing bile acids back into the body from the gut.

As a result, volixibat treatment is expected to lower bile acid levels in the blood which in turn may help ease itch experienced by people with PSC.

Daily 1-minute questionnaire in a mobile phone device, and additional questionnaires at in person visit on an on-site tablet device. Blood Tests, and liver transient elastography (Fibroscan). No biopsy is required.

The study period will be 10 planned study visits over 32 weeks. Some visits can be remote televisits or virtual visits, at the discretion of the investigator. Each on-site visit lasts approximately 4-6 hours.

Every clinical trial sets out strict rules defining who can and can't take part. Find out in the KEY INFORMATION below if you are likely to be eligible.

Summary of main criteria here.

***THIS STUDY IS NOT FOR PEOPLE WHO HAVE HAD TRANSPLANTS***